Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6204]

FDA approves new dosing regimen for pembrolizumab

FDA approves new dosing regimen for pembrolizumab

Researchers' method holds promise for brain study, better tests for viruses and brain cancer

Researchers' method holds promise for brain study, better tests for viruses and brain cancer

A promising new treatment for recurrent paediatric brain cancer

A promising new treatment for recurrent paediatric brain cancer

Major trial shows breast cancer drug can hit prostate cancer Achilles heel

Major trial shows breast cancer drug can hit prostate cancer Achilles heel

A step toward a better way to make gene therapies to attack cancer and genetic disorders

A step toward a better way to make gene therapies to attack cancer and genetic disorders

AACR 2020: Continuous dosing improves progression-free survival for melanoma patients with common mutations

AACR 2020: Continuous dosing improves progression-free survival for melanoma patients with common mutations

New clues about why some metastatic prostate cancers don't respond to enzalutamide

New clues about why some metastatic prostate cancers don't respond to enzalutamide

How COVID-19 is impacting cancer treatment in Australia: challenges of ‘waiting for the storm'

How COVID-19 is impacting cancer treatment in Australia: challenges of ‘waiting for the storm'

New targeted agent produces considerable responses in patients with uterine cancer

New targeted agent produces considerable responses in patients with uterine cancer

A new therapeutic target turns the immune system against lymphoma

A new therapeutic target turns the immune system against lymphoma

More from ecancer